Anti-Inflammatory Activity of Pyrazolo[1,5-a]quinazolines
| Parent link: | Molecules.— .— Basel: MDPI AG Vol. 29, iss. 11.— 2024.— Article number 2421, 24 p. |
|---|---|
| Other Authors: | , , , , , , |
| Summary: | Title screen Chronic inflammation contributes to a number of diseases. Therefore, control of the inflammatory response is an important therapeutic goal. To identify novel anti-inflammatory compounds, we synthesized and screened a library of 80 pyrazolo[1,5-a]quinazoline compounds and related derivatives. Screening of these compounds for their ability to inhibit lipopolysaccharide (LPS)-induced nuclear factor κB (NF-κB) transcriptional activity in human THP-1Blue monocytic cells identified 13 compounds with anti-inflammatory activity (IC50 < 50 µM) in a cell-based test system, with two of the most potent being compounds 13i (5-[(4-sulfamoylbenzyl)oxy]pyrazolo[1,5-a]quinazoline-3-carboxamide) and 16 (5-[(4-(methylsulfinyl)benzyloxy]pyrazolo[1,5-a]quinazoline-3-carboxamide). Pharmacophore mapping of potential targets predicted that 13i and 16 may be ligands for three mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase 2 (ERK2), p38α, and c-Jun N-terminal kinase 3 (JNK3). Indeed, molecular modeling supported that these compounds could effectively bind to ERK2, p38α, and JNK3, with the highest complementarity to JNK3. The key residues of JNK3 important for this binding were identified. Moreover, compounds 13i and 16 exhibited micromolar binding affinities for JNK1, JNK2, and JNK3. Thus, our results demonstrate the potential for developing lead anti-inflammatory drugs based on the pyrazolo[1,5-a]quinazoline and related scaffolds that are targeted toward MAPKs Текстовый файл |
| Language: | English |
| Published: |
2024
|
| Subjects: | |
| Online Access: | https://doi.org/10.3390/molecules29112421 |
| Format: | Electronic Book Chapter |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=683079 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 683079 | ||
| 005 | 20251113110406.0 | ||
| 090 | |a 683079 | ||
| 100 | |a 20251113d2024 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a CH | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a Anti-Inflammatory Activity of Pyrazolo[1,5-a]quinazolines |f Letizia Crocetti, Andrei I. Khlebnikov, Gabriella Guerrini [et al.] | |
| 203 | |a Текст |b визуальный |c электронный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 300 | |a Title screen | ||
| 320 | |a References: 61 tit | ||
| 330 | |a Chronic inflammation contributes to a number of diseases. Therefore, control of the inflammatory response is an important therapeutic goal. To identify novel anti-inflammatory compounds, we synthesized and screened a library of 80 pyrazolo[1,5-a]quinazoline compounds and related derivatives. Screening of these compounds for their ability to inhibit lipopolysaccharide (LPS)-induced nuclear factor κB (NF-κB) transcriptional activity in human THP-1Blue monocytic cells identified 13 compounds with anti-inflammatory activity (IC50 < 50 µM) in a cell-based test system, with two of the most potent being compounds 13i (5-[(4-sulfamoylbenzyl)oxy]pyrazolo[1,5-a]quinazoline-3-carboxamide) and 16 (5-[(4-(methylsulfinyl)benzyloxy]pyrazolo[1,5-a]quinazoline-3-carboxamide). Pharmacophore mapping of potential targets predicted that 13i and 16 may be ligands for three mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase 2 (ERK2), p38α, and c-Jun N-terminal kinase 3 (JNK3). Indeed, molecular modeling supported that these compounds could effectively bind to ERK2, p38α, and JNK3, with the highest complementarity to JNK3. The key residues of JNK3 important for this binding were identified. Moreover, compounds 13i and 16 exhibited micromolar binding affinities for JNK1, JNK2, and JNK3. Thus, our results demonstrate the potential for developing lead anti-inflammatory drugs based on the pyrazolo[1,5-a]quinazoline and related scaffolds that are targeted toward MAPKs | ||
| 336 | |a Текстовый файл | ||
| 461 | 1 | |t Molecules |c Basel |n MDPI AG | |
| 463 | 1 | |t Vol. 29, iss. 11 |v Article number 2421, 24 p. |d 2024 | |
| 610 | 1 | |a pyrazolo[1,5-a]quinazoline | |
| 610 | 1 | |a anti-inflammatory compound | |
| 610 | 1 | |a mitogen-activated protein kinase | |
| 610 | 1 | |a c-Jun N-terminal kinase | |
| 610 | 1 | |a molecular docking | |
| 610 | 1 | |a pharmacophore mapping | |
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 701 | 1 | |a Crocetti |b L. |g Letizia | |
| 701 | 1 | |a Khlebnikov |b A. I. |c Chemist |c Professor of Tomsk Polytechnic University |f 1963- |g Andrey Ivanovich |9 17500 | |
| 701 | 1 | |a Guerrini |b G. |g Gabriella | |
| 701 | 1 | |a Schepetkin (Shchepyotkin) |b I. A. |c doctor-biophysicist |c leading researcher of Tomsk Polytechnic University, candidate of medical science |f 1962- |g Igor Aleksandrovich |9 20276 | |
| 701 | 1 | |a Melani |b F. |g Fabrizio | |
| 701 | 1 | |a Giovannoni |b M. P. |g Maria Paola | |
| 701 | 1 | |a Quinn |b M. T. |g Mark | |
| 801 | 0 | |a RU |b 63413507 |c 20251113 | |
| 850 | |a 63413507 | ||
| 856 | 4 | |u https://doi.org/10.3390/molecules29112421 |z https://doi.org/10.3390/molecules29112421 | |
| 942 | |c CF | ||